Russia is negotiating with 50 countries to supply a coronavirus vaccine developed at the Nikolai Gamaleji Institute of Epidemiological and Microbiological Research in cooperation with the Russian Direct Investment Fund (RDIF) and the Ministry of Defense. The head of the fund, Kirill Dmitrijev, spoke about this on the broadcast of the First Channel.
–
In this context, Dmitry noted that since Russia can produce “only a certain amount” of this vaccines, the number of countries with which RDIF cooperates is also limited.
“We work with 50 countries. We are now focusing mainly on 20 of them, in which we have made great progress, “he said.
The head of RDIF also added that in many countries they are already starting clinical trials of the Russian vaccine. Regulators’ approval could then be obtained in October or November.
“That is why we are focusing on those countries that are interested in the rapid approval of the Russian vaccine and that are showing considerable interest in partnering with Russia,” he explained.
Russian vaccine Sputnik V
At the beginning of August, the Ministry of Health of the Russian Federation registered the first vaccine against covidu-19 developed by experts from the Nikolai Gamaleji Institute of Epidemiological and Microbiological Research with the support of the Russian Direct Investment Fund. It was named Sputnik V and its production has already begun.
The safety of the vaccine was confirmed in a two-phase study involving 38 volunteers. All those who received the vaccine were found to have developed immunity to the infection. The director of the NF Gamaleji Institute, Alexandr Ginzburg, said that the use of the vaccine among citizens will be allowed after the third phase of product research.
Many other countries have already expressed interest in the vaccine, but according to Russia’s health minister, enough benefits must be made for the internal market first. Those who work with sick covid-19 and people from risk groups will be the first to be vaccinated. Mass vaccination in Russia should start in October.
According to information from the State Register of Medicines, the product will be manufactured in the form of a solution for intramuscular administration. Vaccination is planned to carry out in two stages: first with component I and three weeks later with component II. According to the Russian Ministry of Health, this double scheme will allow the creation of long-term immunity for up to two years.
Recall also that this week was deleted the first dose of the vaccine and the third phase of clinical trials began. According to the Minister of Health Mikhail Muraško, more than 30,000 volunteers have already been gathered. A new format has been developed to monitor their health, including a mobile application that allows direct contact between the patient and the vaccine developer.
– .